INmune Bio, Inc. (INMB)

INmune Bio Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	160	203	114	182	232	62
Market Cap Growth	82.70%	78.35%	-37.49%	-21.41%	270.69%	-
Enterprise Value	142	178	77	122	210	56
PE Ratio	-	-6.76	-4.17	-6.00	-19.14	-8.14
PS Ratio	1220.17	1309.19	304.22	1005.53	21052.15	-
PB Ratio	5.66	5.44	1.89	2.27	5.98	2.65
P/FCF Ratio	-11.56	-16.94	-5.02	-6.39	-25.89	-11.60
P/OCF Ratio	-11.56	-16.94	-5.02	-6.39	-25.89	-11.60
EV/Sales Ratio	1082.29	1145.25	205.71	676.39	19069.70	-
EV/EBITDA Ratio	-5.62	-5.92	-2.82	-4.04	-17.34	-7.25
EV/EBIT Ratio	-5.62	-5.92	-2.82	-4.04	-17.34	-7.25
EV/FCF Ratio	-10.58	-14.82	-3.39	-4.30	-23.46	-10.33
Debt / Equity Ratio	0.28	0.28	0.25	0.19	0.00	0.01
Debt / EBITDA Ratio	-0.23	-0.35	-0.56	-0.50	-0.01	-0.02
Debt / FCF Ratio	-0.43	-0.87	-0.67	-0.53	-0.02	-0.03
Quick Ratio	1.49	1.94	4.78	17.16	12.37	9.99
Current Ratio	1.71	2.16	5.92	18.95	13.51	11.09
Asset Turnover	0.00	0.00	0.00	0.00	0	0
Return on Equity (ROE)	-86.20%	-64.10%	-40.50%	-44.10%	-39.00%	-31.30%
Return on Assets (ROA)	-58.40%	-45.60%	-31.40%	-36.30%	-37.20%	-30.40%
Return on Capital (ROIC)	-95.68%	-62.81%	-36.20%	-31.78%	-31.42%	-32.62%
Earnings Yield	-21.58%	-14.79%	-23.99%	-16.67%	-5.22%	-12.29%
FCF Yield	-11.46%	-5.90%	-19.94%	-15.66%	-3.86%	-8.62%
Buyback Yield / Dilution	-0.45%	-0.30%	-11.14%	-34.55%	-16.70%	-18.39%
Total Shareholder Return	-0.45%	-0.30%	-11.14%	-34.55%	-16.70%	-18.39%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).